Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Office-Based Educational Handout for Influenza Vaccination: A Randomized Controlled Trial.

Scott VP, Opel DJ, Reifler J, Rikin S, Pethe K, Barrett A, Stockwell MS.

Pediatrics. 2019 Aug;144(2). pii: e20182580. doi: 10.1542/peds.2018-2580. Epub 2019 Jul 10.

PMID:
31292219
2.

Carbon metabolism modulates the efficacy of drugs targeting the cytochrome bc1:aa3 in Mycobacterium tuberculosis.

Kalia NP, Shi Lee B, Ab Rahman NB, Moraski GC, Miller MJ, Pethe K.

Sci Rep. 2019 Jun 13;9(1):8608. doi: 10.1038/s41598-019-44887-9.

3.

Improving rates of ferrous sulfate prescription for suspected iron deficiency anaemia in infants.

Rea CJ, Bottino C, Chan Yuen J, Conroy K, Cox J, Epee-Bounya A, Kamalia R, Meleedy-Rey P, Pethe K, Samuels R, Schubert P, Starmer AJ.

BMJ Qual Saf. 2019 Jul;28(7):588-597. doi: 10.1136/bmjqs-2018-009098. Epub 2019 Apr 10.

PMID:
30971434
4.

Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer.

Scherr N, Bieri R, Thomas SS, Chauffour A, Kalia NP, Schneide P, Ruf MT, Lamelas A, Manimekalai MSS, Grüber G, Ishii N, Suzuki K, Tanner M, Moraski GC, Miller MJ, Witschel M, Jarlier V, Pluschke G, Pethe K.

Nat Commun. 2018 Dec 18;9(1):5370. doi: 10.1038/s41467-018-07804-8.

5.

Inhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria.

Lee BS, Kalia NP, Jin XEF, Hasenoehrl EJ, Berney M, Pethe K.

J Biol Chem. 2019 Feb 8;294(6):1936-1943. doi: 10.1074/jbc.RA118.005732. Epub 2018 Dec 7.

6.

Target Engagement and Binding Mode of an Antituberculosis Drug to Its Bacterial Target Deciphered in Whole Living Cells by NMR.

Bouvier G, Simenel C, Jang J, Kalia NP, Choi I, Nilges M, Pethe K, Izadi-Pruneyre N.

Biochemistry. 2019 Feb 12;58(6):526-533. doi: 10.1021/acs.biochem.8b00975. Epub 2019 Jan 3.

PMID:
30521325
7.

Why Parents Use the Emergency Department Despite Having a Medical Home.

Pethe K, Baxterbeck A, Rosenthal SL, Stockwell MS.

Clin Pediatr (Phila). 2019 Jan;58(1):95-99. doi: 10.1177/0009922818809447. Epub 2018 Oct 26.

PMID:
30360654
8.

Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.

Foo CS, Lupien A, Kienle M, Vocat A, Benjak A, Sommer R, Lamprecht DA, Steyn AJC, Pethe K, Piton J, Altmann KH, Cole ST.

MBio. 2018 Oct 9;9(5). pii: e01276-18. doi: 10.1128/mBio.01276-18.

9.

Therapeutic potential of promiscuous targets in Mycobacterium tuberculosis.

Lee BS, Pethe K.

Curr Opin Pharmacol. 2018 Oct;42:22-26. doi: 10.1016/j.coph.2018.06.006. Epub 2018 Jul 17. Review.

PMID:
30015177
10.

Developmental Regulation of Effector and Resident Memory T Cell Generation during Pediatric Viral Respiratory Tract Infection.

Connors TJ, Baird JS, Yopes MC, Zens KD, Pethe K, Ravindranath TM, Ho SH, Farber DL.

J Immunol. 2018 Jul 15;201(2):432-439. doi: 10.4049/jimmunol.1800396. Epub 2018 May 30.

11.

Nanoparticles of Short Cationic Peptidopolysaccharide Self-Assembled by Hydrogen Bonding with Antibacterial Effect against Multidrug-Resistant Bacteria.

Hou Z, Shankar YV, Liu Y, Ding F, Subramanion JL, Ravikumar V, Zamudio-Vázquez R, Keogh D, Lim H, Tay MYF, Bhattacharjya S, Rice SA, Shi J, Duan H, Liu XW, Mu Y, Tan NS, Tam KC, Pethe K, Chan-Park MB.

ACS Appl Mater Interfaces. 2017 Nov 8;9(44):38288-38303. doi: 10.1021/acsami.7b12120. Epub 2017 Oct 26.

PMID:
29028315
12.

Bedaquiline Inhibits the ATP Synthase in Mycobacterium abscessus and Is Effective in Infected Zebrafish.

Dupont C, Viljoen A, Thomas S, Roquet-Banères F, Herrmann JL, Pethe K, Kremer L.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01225-17. doi: 10.1128/AAC.01225-17. Print 2017 Nov.

13.

Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection.

Kalia NP, Hasenoehrl EJ, Ab Rahman NB, Koh VH, Ang MLT, Sajorda DR, Hards K, Grüber G, Alonso S, Cook GM, Berney M, Pethe K.

Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):7426-7431. doi: 10.1073/pnas.1706139114. Epub 2017 Jun 26.

14.

Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions.

Cook GM, Hards K, Dunn E, Heikal A, Nakatani Y, Greening C, Crick DC, Fontes FL, Pethe K, Hasenoehrl E, Berney M.

Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0014-2016. Review.

15.

EthA/R-Independent Killing of Mycobacterium tuberculosis by Ethionamide.

Ang MLT, Zainul Rahim SZ, de Sessions PF, Lin W, Koh V, Pethe K, Hibberd ML, Alonso S.

Front Microbiol. 2017 Apr 25;8:710. doi: 10.3389/fmicb.2017.00710. eCollection 2017.

16.

The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD.

Leung JM, Tiew PY, Mac Aogáin M, Budden KF, Yong VF, Thomas SS, Pethe K, Hansbro PM, Chotirmall SH.

Respirology. 2017 May;22(4):634-650. doi: 10.1111/resp.13032. Epub 2017 Mar 25. Review.

PMID:
28342288
17.

Microbiomes in respiratory health and disease: An Asia-Pacific perspective.

Chotirmall SH, Gellatly SL, Budden KF, Mac Aogain M, Shukla SD, Wood DL, Hugenholtz P, Pethe K, Hansbro PM.

Respirology. 2017 Feb;22(2):240-250. doi: 10.1111/resp.12971. Review.

PMID:
28102970
18.

A rheostat mechanism governs the bifurcation of carbon flux in mycobacteria.

Murima P, Zimmermann M, Chopra T, Pojer F, Fonti G, Dal Peraro M, Alonso S, Sauer U, Pethe K, McKinney JD.

Nat Commun. 2016 Aug 24;7:12527. doi: 10.1038/ncomms12527.

19.

Contribution of high-content imaging technologies to the development of anti-infective drugs.

Ang ML, Pethe K.

Cytometry A. 2016 Aug;89(8):755-60. doi: 10.1002/cyto.a.22885. Epub 2016 Jun 6. Review.

20.

Next-generation antimicrobials: from chemical biology to first-in-class drugs.

Ang ML, Murima P, Pethe K.

Arch Pharm Res. 2015 Sep;38(9):1702-17. doi: 10.1007/s12272-015-0645-0. Epub 2015 Aug 11. Review.

21.

Isolation and Characterization of a Hybrid Respiratory Supercomplex Consisting of Mycobacterium tuberculosis Cytochrome bcc and Mycobacterium smegmatis Cytochrome aa3.

Kim MS, Jang J, Ab Rahman NB, Pethe K, Berry EA, Huang LS.

J Biol Chem. 2015 Jun 5;290(23):14350-60. doi: 10.1074/jbc.M114.624312. Epub 2015 Apr 10.

22.

Targeting bacterial central metabolism for drug development.

Murima P, McKinney JD, Pethe K.

Chem Biol. 2014 Nov 20;21(11):1423-32. doi: 10.1016/j.chembiol.2014.08.020. Epub 2014 Oct 16. Review.

23.

High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.

Silva-Miranda M, Ekaza E, Breiman A, Asehnoune K, Barros-Aguirre D, Pethe K, Ewann F, Brodin P, Ballell-Pages L, Altare F.

Antimicrob Agents Chemother. 2015 Jan;59(1):693-7. doi: 10.1128/AAC.03705-14. Epub 2014 Oct 27.

24.

Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities.

Xia X, Pethe K, Kim R, Ballell L, Barros D, Cechetto J, Jeon H, Kim K, Garcia-Bennett AE.

Nanomaterials (Basel). 2014 Sep 11;4(3):813-826. doi: 10.3390/nano4030813.

25.

Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents.

Yokokawa F, Wang G, Chan WL, Ang SH, Wong J, Ma I, Rao SP, Manjunatha U, Lakshminarayana SB, Herve M, Kounde C, Tan BH, Thayalan P, Ng SH, Nanjundappa M, Ravindran S, Gee P, Tan M, Wei L, Goh A, Chen PY, Lee KS, Zhong C, Wagner T, Dix I, Chatterjee AK, Pethe K, Kuhen K, Glynne R, Smith P, Bifani P, Jiricek J.

ACS Med Chem Lett. 2013 Apr 1;4(5):451-5. doi: 10.1021/ml400071a. eCollection 2013 May 9. Erratum in: ACS Med Chem Lett. 2014 Apr 10;5(4):451.

26.

Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.

Kang S, Kim RY, Seo MJ, Lee S, Kim YM, Seo M, Seo JJ, Ko Y, Choi I, Jang J, Nam J, Park S, Kang H, Kim HJ, Kim J, Ahn S, Pethe K, Nam K, No Z, Kim J.

J Med Chem. 2014 Jun 26;57(12):5293-305. doi: 10.1021/jm5003606. Epub 2014 Jun 17.

PMID:
24870926
27.

An ethA-ethR-deficient Mycobacterium bovis BCG mutant displays increased adherence to mammalian cells and greater persistence in vivo, which correlate with altered mycolic acid composition.

Ang ML, Zainul Rahim SZ, Shui G, Dianiškova P, Madacki J, Lin W, Koh VH, Martinez Gomez JM, Sudarkodi S, Bendt A, Wenk M, Mikušová K, Korduláková J, Pethe K, Alonso S.

Infect Immun. 2014 May;82(5):1850-9. doi: 10.1128/IAI.01332-13. Epub 2014 Feb 24. Erratum in: Infect Immun. 2015 Feb;83(2):846. Siti, Zarina Zainul Rahim [corrected to Zainul Rahim, Siti Zarina].

28.

Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.

Rao SP, Lakshminarayana SB, Kondreddi RR, Herve M, Camacho LR, Bifani P, Kalapala SK, Jiricek J, Ma NL, Tan BH, Ng SH, Nanjundappa M, Ravindran S, Seah PG, Thayalan P, Lim SH, Lee BH, Goh A, Barnes WS, Chen Z, Gagaring K, Chatterjee AK, Pethe K, Kuhen K, Walker J, Feng G, Babu S, Zhang L, Blasco F, Beer D, Weaver M, Dartois V, Glynne R, Dick T, Smith PW, Diagana TT, Manjunatha UH.

Sci Transl Med. 2013 Dec 4;5(214):214ra168. doi: 10.1126/scitranslmed.3007355.

29.

Role of the CD137 ligand (CD137L) signaling pathway during Mycobacterium tuberculosis infection.

Martínez Gómez JM, Koh VH, Yan B, Lin W, Ang ML, Rahim SZ, Pethe K, Schwarz H, Alonso S.

Immunobiology. 2014 Jan;219(1):78-86. doi: 10.1016/j.imbio.2013.08.009. Epub 2013 Aug 23.

PMID:
24091276
30.

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim S, Yim SA, Nam J, Kang H, Kwon H, Oh CT, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SP, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Kim J, Oh S, Oh T, Nehrbass U, Han SJ, No Z, Lee J, Brodin P, Cho SN, Nam K, Kim J.

Nat Med. 2013 Sep;19(9):1157-60. doi: 10.1038/nm.3262. Epub 2013 Aug 4.

PMID:
23913123
31.

para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.

Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, Pethe K, Camacho LR.

J Biol Chem. 2013 Aug 9;288(32):23447-56. doi: 10.1074/jbc.M113.475798. Epub 2013 Jun 18. Erratum in: J Biol Chem. 2013 Oct 4;288(40):28951.

32.
33.

Urease activity represents an alternative pathway for Mycobacterium tuberculosis nitrogen metabolism.

Lin W, Mathys V, Ang EL, Koh VH, Martínez Gómez JM, Ang ML, Zainul Rahim SZ, Tan MP, Pethe K, Alonso S.

Infect Immun. 2012 Aug;80(8):2771-9. doi: 10.1128/IAI.06195-11. Epub 2012 May 29.

34.

A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis.

Mak PA, Rao SP, Ping Tan M, Lin X, Chyba J, Tay J, Ng SH, Tan BH, Cherian J, Duraiswamy J, Bifani P, Lim V, Lee BH, Ling Ma N, Beer D, Thayalan P, Kuhen K, Chatterjee A, Supek F, Glynne R, Zheng J, Boshoff HI, Barry CE 3rd, Dick T, Pethe K, Camacho LR.

ACS Chem Biol. 2012 Jul 20;7(7):1190-7. doi: 10.1021/cb2004884. Epub 2012 Apr 25.

35.

[Surgical treatment of pertrochanteric femoral benign tumors in children].

Tomaszewski R, Pethe K, Kler J.

Chir Narzadow Ruchu Ortop Pol. 2011 May-Jun;76(3):151-3. Polish.

PMID:
21961268
36.

The natural product cyclomarin kills Mycobacterium tuberculosis by targeting the ClpC1 subunit of the caseinolytic protease.

Schmitt EK, Riwanto M, Sambandamurthy V, Roggo S, Miault C, Zwingelstein C, Krastel P, Noble C, Beer D, Rao SP, Au M, Niyomrattanakit P, Lim V, Zheng J, Jeffery D, Pethe K, Camacho LR.

Angew Chem Int Ed Engl. 2011 Jun 20;50(26):5889-91. doi: 10.1002/anie.201101740. Epub 2011 May 11. No abstract available.

PMID:
21563281
37.

Nitrate respiration protects hypoxic Mycobacterium tuberculosis against acid- and reactive nitrogen species stresses.

Tan MP, Sequeira P, Lin WW, Phong WY, Cliff P, Ng SH, Lee BH, Camacho L, Schnappinger D, Ehrt S, Dick T, Pethe K, Alonso S.

PLoS One. 2010 Oct 26;5(10):e13356. doi: 10.1371/journal.pone.0013356.

38.

A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.

Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J, Jiricek J, Keller TH, Chatterjee A, Tan MP, Ujjini M, Rao SP, Camacho L, Bifani P, Mak PA, Ma I, Barnes SW, Chen Z, Plouffe D, Thayalan P, Ng SH, Au M, Lee BH, Tan BH, Ravindran S, Nanjundappa M, Lin X, Goh A, Lakshminarayana SB, Shoen C, Cynamon M, Kreiswirth B, Dartois V, Peters EC, Glynne R, Brenner S, Dick T.

Nat Commun. 2010 Aug 24;1:57. doi: 10.1038/ncomms1060.

39.

[Salter pelvic osteotomy in operative treatment in patients with bladder extrophy].

Tomaszewski R, Pethe K, Koszutski T.

Chir Narzadow Ruchu Ortop Pol. 2010 Mar-Apr;75(2):126-8. Polish.

PMID:
20695187
40.

Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection.

Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S.

Proc Natl Acad Sci U S A. 2010 May 25;107(21):9819-24. doi: 10.1073/pnas.1000715107. Epub 2010 May 3.

41.

Coated-platelet levels may explain some variability in clinical phenotypes observed with severe hemophilia.

Saxena K, Pethe K, Dale GL.

J Thromb Haemost. 2010 May;8(5):1140-2. doi: 10.1111/j.1538-7836.2010.03828.x. Epub 2010 Feb 24. No abstract available.

42.

Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability.

Gengenbacher M, Rao SP, Pethe K, Dick T.

Microbiology. 2010 Jan;156(Pt 1):81-7. doi: 10.1099/mic.0.033084-0. Epub 2009 Oct 1.

PMID:
19797356
43.

Triacylglycerol utilization is required for regrowth of in vitro hypoxic nonreplicating Mycobacterium bovis bacillus Calmette-Guerin.

Low KL, Rao PS, Shui G, Bendt AK, Pethe K, Dick T, Wenk MR.

J Bacteriol. 2009 Aug;191(16):5037-43. doi: 10.1128/JB.00530-09. Epub 2009 Jun 12.

44.

[Surgical treatment of adolescent's hallux valgus using Scarf's osteotomy].

Pethe K, Tomaszewski R.

Chir Narzadow Ruchu Ortop Pol. 2008 May-Jun;73(3):184-6. Polish.

PMID:
18847024
45.

The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis.

Rao SP, Alonso S, Rand L, Dick T, Pethe K.

Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11945-50. doi: 10.1073/pnas.0711697105. Epub 2008 Aug 12.

46.

Recombinase-based reporter system and antisense technology to study gene expression and essentiality in hypoxic nonreplicating mycobacteria.

Rao SP, Camacho L, Huat Tan B, Boon C, Russel DG, Dick T, Pethe K.

FEMS Microbiol Lett. 2008 Jul;284(1):68-75. doi: 10.1111/j.1574-6968.2008.01193.x.

47.

Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli.

Boshoff HI, Xu X, Tahlan K, Dowd CS, Pethe K, Camacho LR, Park TH, Yun CS, Schnappinger D, Ehrt S, Williams KJ, Barry CE 3rd.

J Biol Chem. 2008 Jul 11;283(28):19329-41. doi: 10.1074/jbc.M800694200. Epub 2008 May 19.

48.

Sensitive profiling of chemically diverse bioactive lipids.

Shui G, Bendt AK, Pethe K, Dick T, Wenk MR.

J Lipid Res. 2007 Sep;48(9):1976-84. Epub 2007 Jun 12.

49.

Lysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy.

Alonso S, Pethe K, Russell DG, Purdy GE.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6031-6. Epub 2007 Mar 26.

50.

M. tuberculosis Rv2252 encodes a diacylglycerol kinase involved in the biosynthesis of phosphatidylinositol mannosides (PIMs).

Owens RM, Hsu FF, VanderVen BC, Purdy GE, Hesteande E, Giannakas P, Sacchettini JC, McKinney JD, Hill PJ, Belisle JT, Butcher BA, Pethe K, Russell DG.

Mol Microbiol. 2006 Jun;60(5):1152-63.

Supplemental Content

Support Center